Stringent cessation criterion results in better durability of lamivudine treatment: A prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients

Journal of Viral Hepatitis

Volumn 17, Issue 4, 2010, Pages 298-304

  Wang, L ^a   Liu, F ^b   Liu, Y D ^c   Li, X Y ^d   Wang, J B ^d   Zhang, Z H ^d   Wang, Y Z ^d  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c Occupational Disease Hospital of Yantai City   (China)

^d JINAN INFECTIOUS DISEASE HOSPITAL   (China)

Author keywords

Chronic drug therapy; Hepatitis B; Hepatitis B e antigen; Lamivudine therapeutic use; Prospective studies; Recurrence relapse

Indexed keywords

ALPHA INTERFERON; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHINESE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GROUPS BY AGE; HEPATITIS B; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; PROSPECTIVE STUDIES; RECURRENCE; TREATMENT OUTCOME; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 77950214682     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01178.x     Document Type: Article

References (19)

1. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 341 (17 1256 1263.
2. Yao FY, Bass NM. Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000 33 (2 301 307.
3. Schiff ER, Dienstag JL, Karayalcin S et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003 38 (6 818 826.
4. Dienstag JL, Cianciara J, Karayalcin S et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003 37 (4 748 755.
5. Schiff E, Cianciara J, Willems B et al. Durability of HBeAg responses tolamivudine and interferon in the early post-treatment period in adults with chronic hepatitis B. Hepatology 2000 32 (Suppl. 377A.
6. Schiff ER, Cianciara J, Karayalcin S et al. Durable HBeAg and HBsAg seroconversion after, group. I. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (CHB). J Hepatol 2000 2 (Suppl. 99A.
7. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002 9 (3 208 212.
8. Lee HC, Suh DJ, Ryu SH et al. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut 2003 52 (12 1779 1783.
9. Ryu SH, Chung YH, Choi MH et al. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. J Hepatol 2003 39 (4 614 619.
10. Lee CM, Ong GY, Lu SN et al. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002 37 (5 669 674.
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 45 (2 507 539.
12. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus - large-scale analysis using a new genotyping method. J Infect Dis 1997 175 (6 1285 1293.
13. Myers R, Clark C, Khan A, Kellam P, Tedder R. Genotyping Hepatitis B virus from whole- and sub-genomic fragments using position-specific scoring matrices in HBV STAR. J Gen Virol 2006 87 (Pt 6 1459 1464.
14. Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000 32 (4 Pt 1 803 806.
15. Zeuzem S, de Man RA, Honkoop P, Roth WK. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997 27 : 431 436.
16. Chien RN, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology 2003 38 (5 1267 1273.
17. Liaw YF, Leung N, Guan R et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005 25 (3 472 489.
18. Jonas MM, Little NR, Gardner SD. Long-term lamivudine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety. J Viral Hepat 2008 15 (1 20 27.
19. Zeng G, Wang Z, Wen S et al. Geographic distribution, virologic and clinical characteristics of hepatitis B virus genotypes in China. J Viral Hepat 2005 12 (6 609 617.